Developer docs
API playgroundTry for free, no card

Search company profiles

Microbio Co.

Full company profile

uuid0022uft

Namestring
Microbio Co.
Legal namestring
中天生物科技股份有限公司
Websiteurl
twmicrobio.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Microbio Co., Ltd. (TPEx: 4128) is a Taiwanese biotechnology company founded in 2000 and headquartered in Taipei, operating across drug development, postbiotic ingredients, cosmeceuticals, organic retail, and biotech venture investments. Its core technology is the proprietary Symbiota™ precision anaerobic symbiotic co-fermentation platform, which uses multiple gut probiotic strains to produce metabolite-rich postbiotic fermentates that are then formulated across nutraceutical, cosmetic, and pharmaceutical applications.

The product portfolio is built on this single underlying platform. Pharmaceutical assets include MS-20 (MICRSOY oral solution) — Taiwan's first approved oral new drug derived from microbiome technology, shown to enhance PD-1 antibody immunotherapy in late-stage non-small cell lung cancer — plus Herbiron and the SNS851 siRNA weight-loss drug in Phase 1 (Australia, February 2026). Nutraceutical and functional-food ingredients under the Symbiota™ brand include SKUs 020 (gut and immune health), 901 (glucose metabolism and GLP-1 support), 217 (liver health), and 191 (healthy puberty timing). Cosmetic actives comprise Symbiota™ 701 (postbiotic skincare, with published clinical outcomes in atopic dermatitis) and NEXOSOME™ (anti-aging). MB107 cream is a regulated medical device (ISO 13485 certified, March 2025).

Microbio monetizes through a hybrid of one-time drug license revenue (MS-20, Herbiron, Sandipan via Huarun Shuanghe for China), B2B ingredient sales to cosmetic and nutraceutical brands, recurring retail sales through the wholly-owned Cotton Field Organic subsidiary (80 stores in Taiwan under an OMO strategy), and biotech VC investments. Distribution channels span domestic retail, hospital and clinic partnerships for MS-20 education, international B2B sales, and licensing agreements in China. The group structure includes publicly listed affiliates Oneness Biotech (4743) and Diamond Investment (6901), plus operating subsidiaries Microbio (Shanghai) and Cotton Field Organic. Regulatory milestones in 2024–2026 — U.S. GRAS, EU Not Novel food, ISO 13485, Australian HREC/TGA — have opened the U.S., EU, and Australia markets alongside Taiwan and China.

Short descriptiontext

Microbio Co., Ltd. (TPEx: 4128) is a Taiwanese biotech that develops new drugs, postbiotic nutraceutical and cosmetic ingredients, and medical devices from its proprietary Symbiota™ anaerobic co-fermentation platform, serving cancer patients, metabolic-disorder patients, health-conscious consumers, and B2B cosmetic brands across Taiwan, the EU, U.S., China, and Australia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTaipei, Taiwan
HQ citystring
Taipei
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
postbiotic ingredients, biopharmaceutical development, gut microbiome therapeutics, symbiotic fermentation technology, organic health supplements
Industry1 code
PRIMARYHLAAAFAB
Microbiome-Derived Metabolite Therapeutics (postbiotics)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals and Postbiotics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1New Drug Development and Sales
TypeOne Time License
Description

Microbio develops and commercializes novel drugs including MS-20 (approved oral new drug for cancer immunotherapy enhancement) and Herbiron. The company holds drug license permits from Taiwan's Ministry of Health and Welfare for these products.

twmicrobio.com
2Functional Health Supplements
TypeSubscription Recurring
Description

Products developed using the Symbiota technology platform marketed through organic retail channels, including Cotton Field Organic stores. Product lines include Symbiota™ 020 (Gut & Immune Health), Symbiota™ 901 (Glucose Metabolism & GLP-1 Support), Symbiota™ 217 (Liver Health), and Symbiota™ 191 (Healthy Puberty Timing).

twmicrobio.com
3Cosmetic Ingredients
TypeLicensing Royalties
Description

Sale of proprietary postbiotic ingredients (Symbiota™ 701, NEXOSOME™) to cosmetic and skincare brands for incorporation into formulations.

twmicrobio.com
4Organic Products (Cotton Field)
TypeSubscription Recurring
Description

Cotton Field Organic subsidiary operates 80 stores as of 2024, implementing an omnichannel strategy (OMO - Online Merge Offline) to expand store network and promote organic and healthy brand value.

twmicrobio.com
5Biotech Venture Capital Investments
TypeManaged Services
Description

The group is actively engaged in biotech venture capital investments, collaborating with domestic and international research institutions and pharmaceutical companies.

twmicrobio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1Symbiota™
Description

Gut microbiome platform developed through anaerobic symbiotic co-fermentation technology using multiple probiotic strains; includes various functional health formulations and the approved oral new drug MS-20

twmicrobio.com
+7 more records
Core offering1 text field

Microbio Co. is a Taiwanese biotechnology company that develops and commercializes pharmaceutical drugs, postbiotic ingredients, and health supplements based on its proprietary Symbiota™ precision symbiotic fermentation platform. Its portfolio includes approved oral new drugs (MS-20/MICRSOY), cosmetic ingredients, nutraceutical ingredients, siRNA drugs in clinical trials, and an organic retail chain (Cotton Field Organic).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • EASI scores reduced by approximately 48% with Symbiota™ 701 in atopic dermatitis study
+4 more records
Product overview1 text field

Microbio Co. is a biotechnology company offering a diversified portfolio centered on its proprietary Symbiota™ postbiotic technology platform. The core technology uses multiple gut probiotic strains with anaerobic symbiotic co-fermentation to produce metabolite-rich fermentates. The product portfolio includes: (1) nutraceutical ingredients under the Symbiota™ brand (020, 901, 217, 191) for gut health, glucose metabolism, liver health, and puberty support; (2) cosmetic ingredients including Symbiota™ 701 and NEXOSOME™ for skin microbiome and anti-aging applications; (3) new drug development including MS-20 (Taiwan's first approved oral postbiotic drug for cancer immunotherapy support), Herbiron, and SNS851 (siRNA metabolic disorder drug in Phase 1); (4) health supplements including Tien Chun Bao and Li Shizhen Six Flavor Compound; and (5) organic retail operations through subsidiary Cotton Field Organic. The company also provides turnkey solutions and medical device development services.

Product and service2 records
1Symbiota™ Platform
CategoryCore technology platform
Description

Proprietary precision-engineered postbiotic technology platform developed through anaerobic symbiotic co-fermentation using multiple probiotic strains to produce metabolite-rich fermentates for pharmaceutical, nutraceutical and cosmetic applications.

2Symbiota™ 020
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Joint development partnership for SNS851 siRNA drug for metabolic disorders. SNS851 is a novel weight-loss drug with new mechanism of action jointly developed by Oneness Biotech and Microbio (Shanghai). The Phase 1 clinical trial was approved by Australian HREC and acknowledged by TGA in February 2026.

Strategic tierCoreTypeOthers
Description

Subsidiary focused on organic and healthy brand value, implementing omnichannel strategy (OMO) with 80 stores as of 2024. Products developed using Symbiota technology are marketed through Cotton Field Organic retail channels.

Strategic tierCoreTypeOthers
Description

Subsidiary of Microbio Co., Ltd. jointly developing SNS851 with Oneness Biotech. Also developing other products including the '速必一' (Sandipan) medical device.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for commercialization of '速必一' (Sandipan) 香雷糖足膏 in mainland China. Exclusive commercialization licensing agreement signed for the mainland China market.

5Taiwan Cancer Nutrition and Immunity Association
Strategic tierMinorTypeOthers
Description

Social welfare partnership for promoting cancer health education and providing support to cancer patients.

twmicrobio.com
6BoYo Social Welfare Foundation
Strategic tierMinorTypeOthers
Description

Social welfare partnership providing educational resources for children in rural areas.

twmicrobio.com
Strategic tierMinorTypeOthers
Description

Partnership with Cotton Field Organic to promote organic agriculture and donate healthy Lunar New Year dishes to childcare institutions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

US clinical-stage microbiome therapeutics company developing engineered microbial consortia. Comparable as a listed pure-play in microbiome drug development, though focused on different indications.

TypeBroad incumbent
Description

Global bioscience giant combining legacy Chr. Hansen cultures/probiotics with Novozymes enzyme business. Comparable as a broad incumbent in microbial fermentation and postbiotic/probiotic ingredient supply at industrial scale.

TypeBroad incumbent
Description

Irish taste and nutrition multinational that acquired Ganeden, a leading probiotic/postbiotic ingredient company. Directly comparable to Microbio's Symbiota 020/901/217 ingredient lines in B2B functional food and supplement channels.

TypeDirect peer
Description

Taiwanese biotech listed on TPEx (4743) and a strategic Microbio Group affiliate. Co-develops SNS851 siRNA with Microbio (Shanghai) and shares corporate governance ecosystem, making it the most direct comparable in pipeline and listing structure.

5BioGaia
TypeDirect peer
Description

Swedish probiotics and postbiotics company selling probiotic strains, infant nutrition, and gut-health supplements globally. Most directly comparable to Microbio's Symbiota nutraceutical ingredient business and B2B licensing model.

6Lallemand Health Solutions
TypeBroad incumbent
Description

Canadian-based probiotic/postbiotic ingredient supplier serving global nutraceutical brands. Overlaps with Microbio's Symbiota ingredient portfolio and B2B health-supply customers.

7AB Biotics (Hyphens Pharma)
TypeRegional player
Description

Singapore-listed probiotics company with proprietary probiotic strains distributed primarily across Asia. Comparable in probiotic strain R&D and Asian nutraceutical market positioning.

TypeOthers
Description

Part of the Microbio Group ecosystem, providing biotech venture capital exposure. Adjacent rather than competing — relevant for understanding the broader group's strategic asset allocation.

9Second Genome (now BioElectron)
TypeEmerging player
Description

US-based microbiome drug discovery company that pivoted into enzyme therapeutics. Comparable as a peer in microbiome-based drug R&D with platform technology and clinical pipeline ambitions.

TypeEmerging player
Description

Australian microbiome therapeutics company developing oral polyclonal antibodies for gut-related conditions. Comparable to MS-20 as an oral microbiome-derived therapeutic with clinical-stage immuno-oncology adjacency (travel-related diarrhea, gut inflammation).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Microbio Co.

Biopharmaceuticals and Postbioticstwmicrobio.com

Microbio Co., Ltd. (TPEx: 4128) is a Taiwanese biotech that develops new drugs, postbiotic nutraceutical and cosmetic ingredients, and medical devices from its proprietary Symbiota™ anaerobic co-fermentation platform, serving cancer patients, metabolic-disorder patients, health-conscious consumers, and B2B cosmetic brands across Taiwan, the EU, U.S., China, and Australia.

What Microbio Co. does

Microbio Co., Ltd. (TPEx: 4128) is a Taiwanese biotechnology company founded in 2000 and headquartered in Taipei, operating across drug development, postbiotic ingredients, cosmeceuticals, organic retail, and biotech venture investments. Its core technology is the proprietary Symbiota™ precision anaerobic symbiotic co-fermentation platform, which uses multiple gut probiotic strains to produce metabolite-rich postbiotic fermentates that are then formulated across nutraceutical, cosmetic, and pharmaceutical applications.

The product portfolio is built on this single underlying platform. Pharmaceutical assets include MS-20 (MICRSOY oral solution) — Taiwan's first approved oral new drug derived from microbiome technology, shown to enhance PD-1 antibody immunotherapy in late-stage non-small cell lung cancer — plus Herbiron and the SNS851 siRNA weight-loss drug in Phase 1 (Australia, February 2026). Nutraceutical and functional-food ingredients under the Symbiota™ brand include SKUs 020 (gut and immune health), 901 (glucose metabolism and GLP-1 support), 217 (liver health), and 191 (healthy puberty timing). Cosmetic actives comprise Symbiota™ 701 (postbiotic skincare, with published clinical outcomes in atopic dermatitis) and NEXOSOME™ (anti-aging). MB107 cream is a regulated medical device (ISO 13485 certified, March 2025).

Microbio monetizes through a hybrid of one-time drug license revenue (MS-20, Herbiron, Sandipan via Huarun Shuanghe for China), B2B ingredient sales to cosmetic and nutraceutical brands, recurring retail sales through the wholly-owned Cotton Field Organic subsidiary (80 stores in Taiwan under an OMO strategy), and biotech VC investments. Distribution channels span domestic retail, hospital and clinic partnerships for MS-20 education, international B2B sales, and licensing agreements in China. The group structure includes publicly listed affiliates Oneness Biotech (4743) and Diamond Investment (6901), plus operating subsidiaries Microbio (Shanghai) and Cotton Field Organic. Regulatory milestones in 2024–2026 — U.S. GRAS, EU Not Novel food, ISO 13485, Australian HREC/TGA — have opened the U.S., EU, and Australia markets alongside Taiwan and China.

Microbio Co. firmographics

Firmographics
Name
Microbio Co.
Legal name
中天生物科技股份有限公司
Website
https://twmicrobio.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
Microbio Co., Ltd. (TPEx: 4128) is a Taiwanese biotech that develops new drugs, postbiotic nutraceutical and cosmetic ingredients, and medical devices from its proprietary Symbiota™ anaerobic co-fermentation platform, serving cancer patients, metabolic-disorder patients, health-conscious consumers, and B2B cosmetic brands across Taiwan, the EU, U.S., China, and Australia.
Ownership category
akta.pro rank

Microbio Co. industry classification

Industry
Product category
Biopharmaceuticals and Postbiotics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAFAB
Microbiome-Derived Metabolite Therapeutics (postbiotics)

Keywords

  • Postbiotic ingredients
  • Biopharmaceutical development
  • Gut microbiome therapeutics
  • Symbiotic fermentation technology
  • Organic health supplements

Where Microbio Co. is headquartered

Location

Headquarters

HQ city
Taipei
HQ country
Taiwan
HQ region
Asia

Offices3 records

Markets served

Microbio Co. business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. New Drug Development and Sales: Microbio develops and commercializes novel drugs including MS-20 (approved oral new drug for cancer immunotherapy enhancement) and Herbiron. The company holds drug license permits from Taiwan's Ministry of Health and Welfare for these products.
  2. Functional Health Supplements: Products developed using the Symbiota technology platform marketed through organic retail channels, including Cotton Field Organic stores. Product lines include Symbiota™ 020 (Gut & Immune Health), Symbiota™ 901 (Glucose Metabolism & GLP-1 Support), Symbiota™ 217 (Liver Health), and Symbiota™ 191 (Healthy Puberty Timing).
  3. Cosmetic Ingredients: Sale of proprietary postbiotic ingredients (Symbiota™ 701, NEXOSOME™) to cosmetic and skincare brands for incorporation into formulations.
  4. Organic Products (Cotton Field): Cotton Field Organic subsidiary operates 80 stores as of 2024, implementing an omnichannel strategy (OMO - Online Merge Offline) to expand store network and promote organic and healthy brand value.
  5. Biotech Venture Capital Investments: The group is actively engaged in biotech venture capital investments, collaborating with domestic and international research institutions and pharmaceutical companies.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Microbio Co. product offering

Product offering

Core offering

Microbio Co. is a Taiwanese biotechnology company that develops and commercializes pharmaceutical drugs, postbiotic ingredients, and health supplements based on its proprietary Symbiota™ precision symbiotic fermentation platform. Its portfolio includes approved oral new drugs (MS-20/MICRSOY), cosmetic ingredients, nutraceutical ingredients, siRNA drugs in clinical trials, and an organic retail chain (Cotton Field Organic).

Product overview

Microbio Co. is a biotechnology company offering a diversified portfolio centered on its proprietary Symbiota™ postbiotic technology platform. The core technology uses multiple gut probiotic strains with anaerobic symbiotic co-fermentation to produce metabolite-rich fermentates. The product portfolio includes: (1) nutraceutical ingredients under the Symbiota™ brand (020, 901, 217, 191) for gut health, glucose metabolism, liver health, and puberty support; (2) cosmetic ingredients including Symbiota™ 701 and NEXOSOME™ for skin microbiome and anti-aging applications; (3) new drug development including MS-20 (Taiwan's first approved oral postbiotic drug for cancer immunotherapy support), Herbiron, and SNS851 (siRNA metabolic disorder drug in Phase 1); (4) health supplements including Tien Chun Bao and Li Shizhen Six Flavor Compound; and (5) organic retail operations through subsidiary Cotton Field Organic. The company also provides turnkey solutions and medical device development services.

Differentiator

Problem solved

Functional benefit

Brands

  • Symbiota™: Gut microbiome platform developed through anaerobic symbiotic co-fermentation technology using multiple probiotic strains; includes various functional health formulations and the approved oral new drug MS-20
  • MS-20
  • Herbiron
  • Cotton Field Organic
  • Symbiota™ 701
  • NEXOSOME™
  • Tien Chun Bao
  • Li Shizhen Six Flavor Compound

Products and services

  • Symbiota™ Platform Proprietary precision-engineered postbiotic technology platform developed through anaerobic symbiotic co-fermentation using multiple probiotic strains to produce metabolite-rich fermentates for pharmaceutical, nutraceutical and cosmetic applications.
  • Symbiota™ 020

Quantifiable outcome

  • EASI scores reduced by approximately 48% with Symbiota™ 701 in atopic dermatitis study
  • +4 more outcomes

Companies that use Microbio Co.

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Microbio Co. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Microbio Co. partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Oneness Biotech Co., Ltd. (合一生技)coreStrategic or Co-development Partner · 24 February 2026Joint development partnership for SNS851 siRNA drug for metabolic disorders. SNS851 is a novel weight-loss drug with new mechanism of action jointly developed by Oneness Biotech and Microbio (Shanghai). The Phase 1 clinical trial was approved by Australian HREC and acknowledged by TGA in February 2026.
  • Cotton Field Organic (棉花田生機園地)coreOthersSubsidiary focused on organic and healthy brand value, implementing omnichannel strategy (OMO) with 80 stores as of 2024. Products developed using Symbiota technology are marketed through Cotton Field Organic retail channels.
  • Microbio (Shanghai) Co., Ltd. (中天(上海)生物科技有限公司)coreOthersSubsidiary of Microbio Co., Ltd. jointly developing SNS851 with Oneness Biotech. Also developing other products including the '速必一' (Sandipan) medical device.
  • Huarun Shuanghe Pharmaceutical Co., Ltd. (華潤雙鶴藥業)coreStrategic or Co-development PartnerPartnership for commercialization of '速必一' (Sandipan) 香雷糖足膏 in mainland China. Exclusive commercialization licensing agreement signed for the mainland China market.
  • Taiwan Cancer Nutrition and Immunity AssociationminorOthersSocial welfare partnership for promoting cancer health education and providing support to cancer patients.
  • BoYo Social Welfare FoundationminorOthersSocial welfare partnership providing educational resources for children in rural areas.
  • Taishin International BankminorOthersPartnership with Cotton Field Organic to promote organic agriculture and donate healthy Lunar New Year dishes to childcare institutions.

Scale indicators12 records

Recent moves7 records

Expansion highlights7 records

Microbio Co. competitors and assessment

Company assessment

Emerging players

  • Assembly Biosciences: US clinical-stage microbiome therapeutics company developing engineered microbial consortia. Comparable as a listed pure-play in microbiome drug development, though focused on different indications.
  • Second Genome (now BioElectron): US-based microbiome drug discovery company that pivoted into enzyme therapeutics. Comparable as a peer in microbiome-based drug R&D with platform technology and clinical pipeline ambitions.
  • Immuron: Australian microbiome therapeutics company developing oral polyclonal antibodies for gut-related conditions. Comparable to MS-20 as an oral microbiome-derived therapeutic with clinical-stage immuno-oncology adjacency (travel-related diarrhea, gut inflammation).

Broad incumbents

  • Novonesis (formerly Chr. Hansen): Global bioscience giant combining legacy Chr. Hansen cultures/probiotics with Novozymes enzyme business. Comparable as a broad incumbent in microbial fermentation and postbiotic/probiotic ingredient supply at industrial scale.
  • Kerry Group (incl. Ganeden): Irish taste and nutrition multinational that acquired Ganeden, a leading probiotic/postbiotic ingredient company. Directly comparable to Microbio's Symbiota 020/901/217 ingredient lines in B2B functional food and supplement channels.
  • Lallemand Health Solutions: Canadian-based probiotic/postbiotic ingredient supplier serving global nutraceutical brands. Overlaps with Microbio's Symbiota ingredient portfolio and B2B health-supply customers.

Direct peers

  • Oneness Biotech (合一生技): Taiwanese biotech listed on TPEx (4743) and a strategic Microbio Group affiliate. Co-develops SNS851 siRNA with Microbio (Shanghai) and shares corporate governance ecosystem, making it the most direct comparable in pipeline and listing structure.
  • BioGaia: Swedish probiotics and postbiotics company selling probiotic strains, infant nutrition, and gut-health supplements globally. Most directly comparable to Microbio's Symbiota nutraceutical ingredient business and B2B licensing model.

Regional players

  • AB Biotics (Hyphens Pharma): Singapore-listed probiotics company with proprietary probiotic strains distributed primarily across Asia. Comparable in probiotic strain R&D and Asian nutraceutical market positioning.

Others

  • Diamond Biofund: Part of the Microbio Group ecosystem, providing biotech venture capital exposure. Adjacent rather than competing — relevant for understanding the broader group's strategic asset allocation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Microbio Co. social profiles

Digital presence

Microbio Co. compliance and trust

Trust signal

Compliance5 records

Microbio Co. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Microbio Co. leadership team

Management profile

Number of profiles

Profiles3 records

Microbio Co. subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Microbio Co. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Microbio Co. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Microbio Co.

What does Microbio Co. do?

Microbio Co. is a Taiwanese biotechnology company that develops and commercializes pharmaceutical drugs, postbiotic ingredients, and health supplements based on its proprietary Symbiota™ precision symbiotic fermentation platform. Its portfolio includes approved oral new drugs (MS-20/MICRSOY), cosmetic ingredients, nutraceutical ingredients, siRNA drugs in clinical trials, and an organic retail chain (Cotton Field Organic).

Is Microbio Co. a public or private company?

Microbio Co. is a public company. It is classified as public and is currently operating.

When was Microbio Co. founded?

Microbio Co. was founded in 2000. It employs 11 to 50 people.

Where is Microbio Co. based?

Microbio Co. is headquartered in Taipei, Taiwan, in the Asia region.

How does Microbio Co. make money?

Five revenue lines are on record. New Drug Development and Sales are the primary driver. The others are functional Health Supplements, cosmetic Ingredients, organic Products (Cotton Field) and biotech Venture Capital Investments.

Who are Microbio Co.'s main competitors?

Emerging players on record are Assembly Biosciences, Second Genome (now BioElectron) and Immuron. Broad incumbents are Novonesis (formerly Chr. Hansen), Kerry Group (incl. Ganeden) and Lallemand Health Solutions. Direct peers are Oneness Biotech (合一生技) and BioGaia. AB Biotics (Hyphens Pharma) is listed as a regional player. Diamond Biofund is listed as an others.

Does Microbio Co. have an API?

No public API is recorded for Microbio Co..

What industry is Microbio Co. in?

Microbio Co.'s product category is Biopharmaceuticals and Postbiotics. Its primary akta.pro industry code is HLAAAFAB, Microbiome-Derived Metabolite Therapeutics (postbiotics). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales